This study demonstrated limited ORR benefits from a regimen of atezolizumab plus bevacizumab and an acceptable level of safety for patients with advanced non‐squamous NSCLC who had failed EGFR‐TKIs. Here, EGFR is linked to non-small cell lung carcinoma.